Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.05
ZBH's Cash-to-Debt is ranked lower than
97% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. ZBH: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
ZBH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.73 Max: 4.96
Current: 0.05
0.04
4.96
Equity-to-Asset 0.40
ZBH's Equity-to-Asset is ranked lower than
83% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ZBH: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
ZBH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.03  Med: 0.66 Max: 0.84
Current: 0.4
0.03
0.84
Debt-to-Equity 1.00
ZBH's Debt-to-Equity is ranked lower than
89% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. ZBH: 1.00 )
Ranked among companies with meaningful Debt-to-Equity only.
ZBH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.25 Max: 17.37
Current: 1
0.02
17.37
Debt-to-EBITDA 5.19
ZBH's Debt-to-EBITDA is ranked lower than
81% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ZBH: 5.19 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ZBH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.08  Med: 1.1 Max: 9.98
Current: 5.19
0.08
9.98
Interest Coverage 3.05
ZBH's Interest Coverage is ranked lower than
91% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. ZBH: 3.05 )
Ranked among companies with meaningful Interest Coverage only.
ZBH' s Interest Coverage Range Over the Past 10 Years
Min: 1.63  Med: 15.24 Max: 49.46
Current: 3.05
1.63
49.46
Piotroski F-Score: 7
Altman Z-Score: 1.82
Beneish M-Score: -2.84
WACC vs ROIC
7.06%
6.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 13.26
ZBH's Operating Margin % is ranked higher than
77% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. ZBH: 13.26 )
Ranked among companies with meaningful Operating Margin % only.
ZBH' s Operating Margin % Range Over the Past 10 Years
Min: 7.79  Med: 23.06 Max: 28.93
Current: 13.26
7.79
28.93
Net Margin % 8.40
ZBH's Net Margin % is ranked higher than
75% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ZBH: 8.40 )
Ranked among companies with meaningful Net Margin % only.
ZBH' s Net Margin % Range Over the Past 10 Years
Min: 2.45  Med: 16.88 Max: 20.59
Current: 8.4
2.45
20.59
ROE % 6.51
ZBH's ROE % is ranked higher than
64% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. ZBH: 6.51 )
Ranked among companies with meaningful ROE % only.
ZBH' s ROE % Range Over the Past 10 Years
Min: 1.79  Med: 12.78 Max: 15.29
Current: 6.51
1.79
15.29
ROA % 2.44
ZBH's ROA % is ranked higher than
60% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. ZBH: 2.44 )
Ranked among companies with meaningful ROA % only.
ZBH' s ROA % Range Over the Past 10 Years
Min: 0.8  Med: 8.5 Max: 12.27
Current: 2.44
0.8
12.27
ROC (Joel Greenblatt) % 21.95
ZBH's ROC (Joel Greenblatt) % is ranked higher than
69% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. ZBH: 21.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ZBH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.65  Med: 40.69 Max: 64.41
Current: 21.95
11.65
64.41
3-Year Revenue Growth Rate 12.20
ZBH's 3-Year Revenue Growth Rate is ranked higher than
71% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ZBH: 12.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ZBH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.9  Med: 10.55 Max: 25.6
Current: 12.2
4.9
25.6
3-Year EBITDA Growth Rate 2.00
ZBH's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ZBH: 2.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ZBH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.2  Med: 8.05 Max: 39.7
Current: 2
-9.2
39.7
3-Year EPS without NRI Growth Rate -30.70
ZBH's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ZBH: -30.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ZBH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.6  Med: 8.6 Max: 41.7
Current: -30.7
-43.6
41.7
GuruFocus has detected 4 Warning Signs with Zimmer Biomet Holdings Inc ZBH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ZBH's 30-Y Financials

Financials (Next Earnings Date: 2018-01-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ZBH Guru Trades in Q4 2016

Ray Dalio 21,800 sh (New)
Robert Olstein 171,825 sh (+160.34%)
Jeremy Grantham 682,179 sh (+25.51%)
Scott Black 22,392 sh (+19.85%)
Mairs and Power 979,037 sh (+15.44%)
John Rogers 1,129,553 sh (+12.38%)
HOTCHKIS & WILEY 1,591,659 sh (+10.26%)
Richard Snow 305,661 sh (+3.71%)
Jeff Auxier 86,514 sh (+3.28%)
Eaton Vance Worldwide Health Sciences Fund 282,439 sh (+14.05%)
First Eagle Investment 873 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 450,000 sh (-0.51%)
Mario Gabelli 223,982 sh (-1.79%)
Ken Fisher 147,258 sh (-4.33%)
Private Capital 96,514 sh (-7.04%)
Pioneer Investments 75,459 sh (-30.76%)
Steven Cohen 319,000 sh (-34.53%)
Joel Greenblatt 33,733 sh (-79.03%)
Paul Tudor Jones 3,000 sh (-99.29%)
» More
Q1 2017

ZBH Guru Trades in Q1 2017

Larry Robbins 771,410 sh (New)
John Buckingham 41,124 sh (New)
Caxton Associates 3,300 sh (New)
Paul Tudor Jones 260,450 sh (+8581.67%)
Joel Greenblatt 164,266 sh (+386.96%)
Steven Cohen 1,053,500 sh (+230.25%)
Richard Snow 535,924 sh (+75.33%)
Pioneer Investments 120,968 sh (+60.31%)
Mario Gabelli 275,242 sh (+22.89%)
Mairs and Power 1,059,960 sh (+8.27%)
Scott Black 22,647 sh (+1.14%)
Jeff Auxier 86,614 sh (+0.12%)
Eaton Vance Worldwide Health Sciences Fund 282,439 sh (unchged)
Ray Dalio Sold Out
Private Capital 96,339 sh (-0.18%)
PRIMECAP Management 443,800 sh (-1.38%)
HOTCHKIS & WILEY 1,555,689 sh (-2.26%)
Jeremy Grantham 664,573 sh (-2.58%)
John Rogers 1,076,908 sh (-4.66%)
Ken Fisher 132,791 sh (-9.82%)
Robert Olstein 136,645 sh (-20.47%)
First Eagle Investment 494 sh (-43.41%)
» More
Q2 2017

ZBH Guru Trades in Q2 2017

Richard Pzena 2,023 sh (New)
Jana Partners 3,195,300 sh (New)
Andreas Halvorsen 397,654 sh (New)
David Dreman 8,236 sh (New)
Scott Black 42,878 sh (+89.33%)
PRIMECAP Management 665,600 sh (+49.98%)
Mario Gabelli 312,843 sh (+13.66%)
John Buckingham 44,429 sh (+8.04%)
Jeremy Grantham 680,934 sh (+2.46%)
Mairs and Power 1,078,427 sh (+1.74%)
First Eagle Investment 494 sh (unchged)
Jana Partners 804,700 sh (unchged)
Steven Cohen 75,000 sh (unchged)
Larry Robbins 771,410 sh (unchged)
Jeff Auxier 86,614 sh (unchged)
Caxton Associates Sold Out
Ken Fisher 132,184 sh (-0.46%)
John Rogers 1,062,051 sh (-1.38%)
Private Capital 94,939 sh (-1.45%)
Richard Snow 524,554 sh (-2.12%)
HOTCHKIS & WILEY 1,419,564 sh (-8.75%)
Pioneer Investments 108,068 sh (-10.66%)
Robert Olstein 110,760 sh (-18.94%)
Steven Cohen 618,700 sh (-41.27%)
Joel Greenblatt 87,579 sh (-46.68%)
Paul Tudor Jones 14,929 sh (-94.27%)
Eaton Vance Worldwide Health Sciences Fund 202,239 sh (-28.40%)
» More
Q3 2017

ZBH Guru Trades in Q3 2017

George Soros 62,500 sh (New)
Barrow, Hanley, Mewhinney & Strauss 355 sh (New)
Larry Robbins 3,155,386 sh (+309.04%)
David Dreman 16,472 sh (+100.00%)
Joel Greenblatt 156,568 sh (+78.77%)
Mario Gabelli 485,919 sh (+55.32%)
Jana Partners 4,662,497 sh (+45.92%)
Robert Olstein 132,700 sh (+19.81%)
Steven Cohen 697,900 sh (+12.80%)
John Buckingham 46,108 sh (+3.78%)
Mairs and Power 1,096,486 sh (+1.67%)
Richard Pzena 2,023 sh (unchged)
First Eagle Investment 494 sh (unchged)
Pioneer Investments Sold Out
Andreas Halvorsen Sold Out
Jeff Auxier 86,544 sh (-0.08%)
John Rogers 1,057,463 sh (-0.43%)
PRIMECAP Management 661,100 sh (-0.68%)
Richard Snow 517,234 sh (-1.40%)
Ken Fisher 130,255 sh (-1.46%)
Jeremy Grantham 641,484 sh (-5.79%)
HOTCHKIS & WILEY 1,336,964 sh (-5.82%)
Private Capital 88,219 sh (-7.08%)
Scott Black 21,573 sh (-49.69%)
Paul Tudor Jones 4,150 sh (-72.20%)
Eaton Vance Worldwide Health Sciences Fund 182,716 sh (-9.65%)
» More
» Details

Insider Trades

Latest Guru Trades with ZBH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2017-09-30 Reduce -5.82%0.04%$110.13 - $132.61 $ 115.24-3%1,336,964
John Rogers 2017-09-30 Reduce -0.43%0.01%$110.13 - $132.61 $ 115.24-3%1,057,463
Mario Gabelli 2017-09-30 Add 55.32%0.12%$110.13 - $132.61 $ 115.24-3%485,919
Joel Greenblatt 2017-09-30 Add 78.77%0.12%$110.13 - $132.61 $ 115.24-3%156,568
Robert Olstein 2017-09-30 Add 19.81%0.33%$110.13 - $132.61 $ 115.24-3%132,700
Ken Fisher 2017-09-30 Reduce -1.46%$110.13 - $132.61 $ 115.24-3%130,255
Private Capital 2017-09-30 Reduce -7.08%0.14%$110.13 - $132.61 $ 115.24-3%88,219
George Soros 2017-09-30 New Buy0.22%$110.13 - $132.61 $ 115.24-3%62,500
David Dreman 2017-09-30 Add 100.00%0.56%$110.13 - $132.61 $ 115.24-3%16,472
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 New Buy$110.13 - $132.61 $ 115.24-3%355
HOTCHKIS & WILEY 2017-06-30 Reduce -8.75%0.06%$116.54 - $129.39 $ 115.24-6%1,419,564
John Rogers 2017-06-30 Reduce -1.38%0.02%$116.54 - $129.39 $ 115.24-6%1,062,051
Mario Gabelli 2017-06-30 Add 13.66%0.03%$116.54 - $129.39 $ 115.24-6%312,843
Ken Fisher 2017-06-30 Reduce -0.46%$116.54 - $129.39 $ 115.24-6%132,184
Robert Olstein 2017-06-30 Reduce -18.94%0.41%$116.54 - $129.39 $ 115.24-6%110,760
Private Capital 2017-06-30 Reduce -1.45%0.03%$116.54 - $129.39 $ 115.24-6%94,939
Joel Greenblatt 2017-06-30 Reduce -46.68%0.12%$116.54 - $129.39 $ 115.24-6%87,579
David Dreman 2017-06-30 New Buy0.58%$116.54 - $129.39 $ 115.24-6%8,236
Richard Pzena 2017-06-30 New Buy$116.54 - $129.39 $ 115.24-6%2,023
HOTCHKIS & WILEY 2017-03-31 Reduce -2.26%0.01%$103.33 - $122.11 $ 115.24-1%1,555,689
John Rogers 2017-03-31 Reduce -4.66%0.06%$103.33 - $122.11 $ 115.24-1%1,076,908
Mario Gabelli 2017-03-31 Add 22.89%0.04%$103.33 - $122.11 $ 115.24-1%275,242
Joel Greenblatt 2017-03-31 Add 386.96%0.2%$103.33 - $122.11 $ 115.24-1%164,266
Robert Olstein 2017-03-31 Reduce -20.47%0.47%$103.33 - $122.11 $ 115.24-1%136,645
Ken Fisher 2017-03-31 Reduce -9.82%$103.33 - $122.11 $ 115.24-1%132,791
Private Capital 2017-03-31 Reduce -0.18%$103.33 - $122.11 $ 115.24-1%96,339
First Eagle Investment 2017-03-31 Reduce -43.41%$103.33 - $122.11 $ 115.24-1%494
HOTCHKIS & WILEY 2016-12-31 Add 10.26%0.06%$97.99 - $132.74 $ 115.244%1,591,659
John Rogers 2016-12-31 Add 12.38%0.15%$97.99 - $132.74 $ 115.244%1,129,553
Mario Gabelli 2016-12-31 Reduce -1.79%$97.99 - $132.74 $ 115.244%223,982
Robert Olstein 2016-12-31 Add 160.34%1.41%$97.99 - $132.74 $ 115.244%171,825
Ken Fisher 2016-12-31 Reduce -4.33%$97.99 - $132.74 $ 115.244%147,258
Private Capital 2016-12-31 Reduce -7.04%0.14%$97.99 - $132.74 $ 115.244%96,514
Joel Greenblatt 2016-12-31 Reduce -79.03%0.21%$97.99 - $132.74 $ 115.244%33,733
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NYSE:EW, NAS:ALGN, LSE:SN., NYSE:TFX, XSWX:SOON, NYSE:VAR, NAS:ABMD, ASX:COH, OCSE:WDH, NYSE:BSX, XPAR:DIM, SZSE:300003, NZSE:FPH, LSE:CTEC, NAS:MASI, OCSE:GN, NAS:LIVN, NAS:IART, NYSE:GMED, NYSE:PEN » details
Traded in other countries:ZIM.Germany, ZBH.Switzerland, 0QQD.UK,
Headquarter Location:USA
Zimmer Biomet Holdings Inc is a medical device company. It designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery under brands like NexGen, VerSys, SoPlus, and Pulsavac.

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. It distributes and sells its products to hospitals and clinics worldwide under brand names like NexGen, Zimmer, VerSys, SoPlus, and Pulsavac.

Guru Investment Theses on Zimmer Biomet Holdings Inc

Jeff Auxier Comments on Zimmer Biomet Holdings - May 09, 2017

Zimmer Biomet (NYSE:ZBH) has a leading musculoskeletal portfolio and is the global market share leader in knees and hips. Zimmer is also predicting $2B in annual free cash flow by 2020. At year end the stock traded down to a steep discount to the market, an attractive 12 times earnings. The demographics favor hips and knees as the peak year is age 68—about the average age for baby boomers. According to the Pew Research Center, roughly 10,000 Americans turn 65 every day. Pain is a good motivator for action.

From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

John Rogers Comments on Zimmer Biomet Holdings - Jan 20, 2017

Other holdings underperformed. Orthopedic specialist Zimmer Biomet Holdings, Inc. (NYSE:ZBH) fell –20.44% after cutting guidance and admitting internal supply issues. Earnings were in-line, but revenue was negatively impacted by inventory for some high-end products. The company subsequently cut full-year earnings guidance from $8.00 per share to $ 7.95 per share. We view the supply problem as a short-term issue and believe the long-term future is bright for this best-in-class brand.

From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund fourth quarter 2016 commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Zimmer Biomet Holdings Inc

Zimmer Biomet to Present at 29th Annual Piper Jaffray Healthcare Conference
Report: Exploring Fundamental Drivers Behind CalAtlantic, EOG, Treehouse, Zimmer Biomet, NiSource, and Viavi – New Horizons, Emerging Trends, and Upcoming Developments
Zimmer Biomet to Present at Jefferies 2017 London Healthcare Conference
Zimmer Biomet Announces U.S. Launch of Vitality®+ and Vital™ Spinal Fixation Systems
Zimmer Biomet Holdings Announces Audio Webcast and Conference Call of Third Quarter 2017 Results
Zimmer Biomet Announces U.S. Launch of Avenue® T TLIF Cage with Integrated VerteBRIDGE® Plating
Zimmer Biomet Announces Global Launch of the Persona® Partial Knee System
Zimmer Biomet Holdings to Present at Morgan Stanley 15th Annual Global Healthcare Conference
David Dreman’s Top 5 Health Care Buys for the 2nd Quarter Guru takes new positions in stocks he previously sold
Dreman Value Management founder David Dreman (Trades, Portfolio) established 210 new positions in the second quarter, of which 20 were in health care companies. His top five health care buys were Aetna Inc. (NYSE:AET), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Amgen Inc. (NASDAQ:AMGN), Biogen Inc. (NASDAQ:BIIB) and Cardinal Health Inc. (NYSE:CAH). Read more...
Scott Black Establishes 4 New Positions in 2nd Quarter Guru releases quarterly portfolio
Delphi Management founder Scott Black (Trades, Portfolio) established four new positions in the second quarter: Dick’s Sporting Goods Inc. (NYSE:DKS), Nova Measuring Instruments Ltd. (NASDAQ:NVMI), Cohu Inc. (NASDAQ:COHU) and AECOM (NYSE:ACM). Read more...

Ratios

vs
industry
vs
history
PE Ratio 36.13
ZBH's PE Ratio is ranked lower than
56% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. ZBH: 36.13 )
Ranked among companies with meaningful PE Ratio only.
ZBH' s PE Ratio Range Over the Past 10 Years
Min: 9.07  Med: 20.8 Max: 397
Current: 36.13
9.07
397
Forward PE Ratio 13.61
ZBH's Forward PE Ratio is ranked higher than
95% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ZBH: 13.61 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 36.13
ZBH's PE Ratio without NRI is ranked lower than
58% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. ZBH: 36.13 )
Ranked among companies with meaningful PE Ratio without NRI only.
ZBH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.07  Med: 20.8 Max: 397
Current: 36.13
9.07
397
Price-to-Owner-Earnings 17.02
ZBH's Price-to-Owner-Earnings is ranked higher than
79% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 37.10 vs. ZBH: 17.02 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ZBH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.03  Med: 20.37 Max: 110.83
Current: 17.02
9.03
110.83
PB Ratio 2.23
ZBH's PB Ratio is ranked higher than
62% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ZBH: 2.23 )
Ranked among companies with meaningful PB Ratio only.
ZBH' s PB Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.21 Max: 4.21
Current: 2.23
1.31
4.21
PS Ratio 3.02
ZBH's PS Ratio is ranked higher than
50% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. ZBH: 3.02 )
Ranked among companies with meaningful PS Ratio only.
ZBH' s PS Ratio Range Over the Past 10 Years
Min: 1.82  Med: 3.11 Max: 6.16
Current: 3.02
1.82
6.16
Price-to-Free-Cash-Flow 18.13
ZBH's Price-to-Free-Cash-Flow is ranked higher than
68% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. ZBH: 18.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ZBH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.53  Med: 21.87 Max: 50.44
Current: 18.13
9.53
50.44
Price-to-Operating-Cash-Flow 12.97
ZBH's Price-to-Operating-Cash-Flow is ranked higher than
71% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. ZBH: 12.97 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ZBH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.88  Med: 13.72 Max: 25.25
Current: 12.97
6.88
25.25
EV-to-EBIT 34.77
ZBH's EV-to-EBIT is ranked lower than
70% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. ZBH: 34.77 )
Ranked among companies with meaningful EV-to-EBIT only.
ZBH' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 14.7 Max: 80.8
Current: 34.77
6.8
80.8
EV-to-EBITDA 16.58
ZBH's EV-to-EBITDA is ranked higher than
53% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. ZBH: 16.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZBH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 11.3 Max: 34
Current: 16.58
5.6
34
EV-to-Revenue 4.29
ZBH's EV-to-Revenue is ranked lower than
59% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. ZBH: 4.29 )
Ranked among companies with meaningful EV-to-Revenue only.
ZBH' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 3.6 Max: 6.4
Current: 4.29
1.9
6.4
Shiller PE Ratio 31.71
ZBH's Shiller PE Ratio is ranked higher than
73% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 50.47 vs. ZBH: 31.71 )
Ranked among companies with meaningful Shiller PE Ratio only.
ZBH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.13  Med: 25.27 Max: 37.11
Current: 31.71
15.13
37.11
Current Ratio 1.47
ZBH's Current Ratio is ranked lower than
78% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. ZBH: 1.47 )
Ranked among companies with meaningful Current Ratio only.
ZBH' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.83 Max: 13.11
Current: 1.47
1.14
13.11
Quick Ratio 0.78
ZBH's Quick Ratio is ranked lower than
86% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ZBH: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
ZBH' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 1.81 Max: 11.78
Current: 0.78
0.71
11.78
Days Inventory 341.31
ZBH's Days Inventory is ranked lower than
89% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. ZBH: 341.31 )
Ranked among companies with meaningful Days Inventory only.
ZBH' s Days Inventory Range Over the Past 10 Years
Min: 284.64  Med: 317.55 Max: 349.41
Current: 341.31
284.64
349.41
Days Sales Outstanding 61.99
ZBH's Days Sales Outstanding is ranked higher than
51% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. ZBH: 61.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZBH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.15  Med: 70.01 Max: 88.03
Current: 61.99
63.15
88.03
Days Payable 55.19
ZBH's Days Payable is ranked higher than
51% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ZBH: 55.19 )
Ranked among companies with meaningful Days Payable only.
ZBH' s Days Payable Range Over the Past 10 Years
Min: 42.16  Med: 52.73 Max: 72.55
Current: 55.19
42.16
72.55

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.83
ZBH's Dividend Yield % is ranked lower than
67% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 1.38 vs. ZBH: 0.83 )
Ranked among companies with meaningful Dividend Yield % only.
ZBH' s Dividend Yield % Range Over the Past 10 Years
Min: 0.28  Med: 0.83 Max: 1.1
Current: 0.83
0.28
1.1
Dividend Payout Ratio 0.30
ZBH's Dividend Payout Ratio is ranked higher than
79% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 0.36 vs. ZBH: 0.30 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ZBH' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.17  Med: 0.21 Max: 1.14
Current: 0.3
0.17
1.14
3-Year Dividend Growth Rate 6.30
ZBH's 3-Year Dividend Growth Rate is ranked lower than
61% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 10.90 vs. ZBH: 6.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ZBH' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.9
Current: 6.3
0
6.9
Forward Dividend Yield % 0.83
ZBH's Forward Dividend Yield % is ranked lower than
71% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ZBH: 0.83 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.83
ZBH's 5-Year Yield-on-Cost % is ranked lower than
69% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. ZBH: 0.83 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ZBH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.28  Med: 0.83 Max: 1.1
Current: 0.83
0.28
1.1
3-Year Average Share Buyback Ratio -5.70
ZBH's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. ZBH: -5.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZBH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.3  Med: 1.65 Max: 7.5
Current: -5.7
-8.3
7.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.36
ZBH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. ZBH: 1.36 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ZBH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.58  Med: 1.11 Max: 2.24
Current: 1.36
0.58
2.24
Price-to-Median-PS-Value 0.97
ZBH's Price-to-Median-PS-Value is ranked higher than
56% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. ZBH: 0.97 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZBH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.65  Med: 1.19 Max: 2.98
Current: 0.97
0.65
2.98
Earnings Yield (Greenblatt) % 2.88
ZBH's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. ZBH: 2.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZBH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 6.8 Max: 14.7
Current: 2.88
1.2
14.7
Forward Rate of Return (Yacktman) % 5.91
ZBH's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. ZBH: 5.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ZBH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.7  Med: 11.9 Max: 36.7
Current: 5.91
0.7
36.7

More Statistics

Revenue (TTM) (Mil) $7,762.90
EPS (TTM) $ 3.19
Beta1.14
Short Percentage of Float2.17%
52-Week Range $99.11 - 133.49
Shares Outstanding (Mil)171.60

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 7,787 7,922 8,164 8,445
EPS ($) 8.10 8.45 9.04 9.77
EPS without NRI ($) 8.10 8.45 9.04 9.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.26%
Dividends per Share ($) 1.00 1.06 1.25

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}